Compare SPB & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPB | COLL |
|---|---|---|
| Founded | 1906 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.2B |
| IPO Year | 1994 | 2015 |
| Metric | SPB | COLL |
|---|---|---|
| Price | $73.62 | $34.48 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | ★ $82.40 | $50.83 |
| AVG Volume (30 Days) | 320.7K | ★ 400.6K |
| Earning Date | 05-07-2026 | 05-28-2026 |
| Dividend Yield | ★ 2.53% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | 1.21 | ★ 1.73 |
| Revenue | ★ $3,802,100,000.00 | $780,567,000.00 |
| Revenue This Year | $1.78 | $6.07 |
| Revenue Next Year | $1.85 | N/A |
| P/E Ratio | $61.36 | ★ $20.21 |
| Revenue Growth | 20.86 | ★ 23.62 |
| 52 Week Low | $49.99 | $23.23 |
| 52 Week High | $80.42 | $50.79 |
| Indicator | SPB | COLL |
|---|---|---|
| Relative Strength Index (RSI) | 45.41 | 16.51 |
| Support Level | $51.36 | $34.30 |
| Resistance Level | $80.42 | $36.20 |
| Average True Range (ATR) | 2.35 | 1.59 |
| MACD | -0.95 | -0.70 |
| Stochastic Oscillator | 3.36 | 2.18 |
Spectrum Brands Holdings Inc is consumer products and home essentials company. The company is a supplier of consumer batteries, residential locksets, residential builders' hardware, grooming products and personal care products. The company manages the businesses in product-focused segments; Home and Personal Care, global Pet Care, and Home and Garden. The Company manufactures, markets and distributes its products globally in the North America, Europe, Middle East & Africa, Latin America, and Asia-Pacific.
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.